- Home
- WEA vs IMUX Comparison
WEA vs IMUX Comparison
Compare WEA & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WEA | IMUX |
|---|---|---|
| Founded | 2002 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.2M | 152.6M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | WEA | IMUX |
|---|---|---|
| Price | $10.85 | $1.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.80 |
| AVG Volume (30 Days) | 28.7K | ★ 2.3M |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 7.87% | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.16 | $0.51 |
| 52 Week High | $11.44 | $1.51 |
Technical Indicators
Market Signals| Indicator | WEA | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 56.45 | 54.43 |
| Support Level | $10.65 | $1.05 |
| Resistance Level | $10.85 | $1.35 |
| Average True Range (ATR) | 0.14 | 0.09 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 83.61 | 50.00 |
Price Performance
Historical ComparisonAbout WEA Western Asset Bond Fund Share of Beneficial Interest
Western Asset Premier Bond Fund is a diversified closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The Fund invests in sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.